ADC (antibody-drug conjugates) Loading...

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
22:50
Jan 07
Kim Seon-ah Senior Research Fellow, Hana Securities Research Center 3PRO TV (삼프로TV)
ADC remains major biotech theme
The speaker views ADC as a major 2026 biotech area requiring substantial research. Korean ADC names include LigaChem Biosciences as a leader, newly listed IntoCell, AimedBio, and traditional capital-rich R&D companies such as Celltrion. Investors should watch these ADC names.
ADC (antibody-drug conjugates)
MED

About ADC (antibody-drug conjugates) Investor Commentary

Across the available history and selected sources, Buzzberg tracks ADC (antibody-drug conjugates) across 1 sources: 0 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 0% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Kim Seon-ah.